Nematrelvir/Ritonavir combination (Nirmatrelvir/Ritonavir) Pfizer’s efficacy

Nirmatrelvir/Ritonavir tablet combination Paxlovid (Nirmatrelvir/Ritonavir) was developed by Pfizer and approved by the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration for sale domestically and overseas. Mild-to-moderate coronavirus disease 2019 (COVID-19), including hospitalization or death, in adults at high risk for COVID-19 infection An oral antiviral drug successfully reduced the risk of hospitalization by 89% in patients at high risk of COVID-19 infection progressing to severe disease when taken within 3 days of symptom onset, final data from a study show. Taking it within 5 days of symptoms can reduce the risk of hospitalization by 88%.